US Stock MarketDetailed Quotes
CTOR Citius Oncology
- 1.020
- +0.024+2.43%
Trading Nov 27 09:59 ET
72.74MMarket Cap-4435P/E (TTM)
1.070High0.990Low22.11KVolume0.995Open0.996Pre Close22.60KTurnover0.42%Turnover RatioLossP/E (Static)71.30MShares49.00052wk High1.51P/B5.36MFloat Cap0.85052wk Low--Dividend TTM5.25MShs Float49.000Historical High--Div YieldTTM8.02%Amplitude0.850Historical Low1.022Avg Price1Lot Size
About Citius Oncology Company
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Company Profile
SymbolCTOR
Company NameCitius Oncology
Listing DateDec 8, 2022
Founded2021
CEOMr. Leonard L. Mazur
MarketNASDAQ
Fiscal Year Ends12-31
Address11 Commerce Drive,1st floor
CityCranford
ProvinceNew Jersey
CountryUnited States of America
Zip Code07016
Company Executives
- Name
- Position
- Salary
- Leonard L. Mazur
- Chairman of the Board and Chief Executive Officer
- --
- Jaime Bartushak
- Chief Financial Officer and Treasurer
- --
- Dr. Myron Czuczman, M.D.
- Chief Medical Officer
- --
- Myron Z. Holubiak
- Director and Secretary
- --
- Suren G. Dutia
- Independent Director
- --
- Robert J. Smith
- Independent Director
- --
- Carol Webb
- Independent Director
- --
- Joel D. Mayersohn
- Independent Director
- --
- Dennis M. McGrath, C.P.A.
- Independent Director
- --
- Dr. Eugene Holuka
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
